Jean Husten

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Sheila Miknyoczki, Hong Chang, Jennifer V. Grobelny et al. · Molecular Cancer Therapeutics · 2007 · 112 citations

Medicine, Oncology, Pharmacology +15

An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease

Adam W. Clarke, Lynn D. Poulton, Doris Shim et al. · mAbs · 2018 · 56 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Synthesis and structure–activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors

Ming Tao, Chung Ho Park, Ron Bihovsky et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 48 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Mixed-Lineage Kinase 1 and Mixed-Lineage Kinase 3 Subtype-Selective Dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, Mixed-Lineage Kinase 1 Crystallography, and Oral in Vivo Activity in 1-Methyl-4-phenyltetrahydropyridine Models

Robert L. Hudkins, James L. Diebold, Ming Tao et al. · Journal of Medicinal Chemistry · 2008 · 43 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Higher Binding Affinity and <i>In Vitro</i> Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab

Mark T. Liddament, Jean Husten, Tanya Estephan et al. · Allergy Asthma and Immunology Research · 2019 · 25 citations · Full text

Medicine, Immunology, Pharmacology +14